Approved by the FDA in 2000, Linezolid introduced the oxazolidinone class into clinical practice. Its activity against susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), made it useful where established antibiotics faced resistance. Its molecular architecture helps explain how it engages the bacterial ribosome.
Three Parts of One Molecule
The Linezolid structure combines an oxazolidinone ring, a substituted aromatic region and an acetamidomethyl side chain. Its formula is C16H20FN3O4, with a molecular weight of 337.35 g/mol.
The five-membered oxazolidinone ring carries a phenyl group on its nitrogen. This phenyl group bears fluorine and a morpholine ring, while carbon 5 of the oxazolidinone carries the side chain. Carbon 5 is a stereocenter with the (S)-configuration. This defines the arrangement of substituents at that center, an important feature when comparing related oxazolidinones.
Where the Drug Binds
Linezolid binds within the peptidyl transferase center of the 50S ribosomal subunit, interacting with 23S rRNA. This region positions substrates for peptide bond formation.
The label describes prevention of functional 70S initiation-complex formation. Later translation and structural studies show that linezolid can also stall elongating ribosomes, with inhibition depending on the amino acid sequence of the growing peptide. Describing it solely as a blocker of the first stage of translation therefore misses an important part of its mechanism.
What the Mechanism Means in Practice
Time-kill studies described in the label found linezolid bacteriostatic against staphylococci and enterococci, and bactericidal against most streptococcal isolates. Bacteriostatic activity limits growth, whereas bactericidal activity reduces viable bacterial counts.
Resistance can arise through changes around the ribosomal binding site. Two established routes include:
- mutations in genes encoding 23S rRNA, such as G2576T;
- acquisition of cfr, which encodes a methyltransferase that modifies 23S rRNA.
Cfr-mediated modification can confer resistance to several antibiotic classes, so a distinct binding mode does not guarantee absence of cross-resistance.
Linezolid is available orally and intravenously. Its approximately 100% oral bioavailability allows a route switch without dose adjustment, as described in the label.
A Note for Laboratory Users
Linezolid also reversibly inhibits monoamine oxidase, a separate pharmacological action from its antibacterial mechanism. As a reference oxazolidinone, it supports ribosome studies, susceptibility testing and comparisons with new analogs. For structure-activity work, documenting stereochemistry alongside assay conditions helps keep comparisons meaningful.